These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3. Pufahl L; Katryniok C; Schnur N; Sorg BL; Metzner J; Grez M; Steinhilber D J Cell Mol Med; 2012 Jul; 16(7):1461-73. PubMed ID: 21883892 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells. Zhou Q; Dalgard CL; Wynder C; Doughty ML BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133 [TBL] [Abstract][Full Text] [Related]
7. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation. Hutt DM; Roth DM; Marchal C; Bouchecareilh M Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814 [TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs). Mackmull MT; Iskar M; Parca L; Singer S; Bork P; Ori A; Beck M Mol Cell Proteomics; 2015 May; 14(5):1350-60. PubMed ID: 25755299 [TBL] [Abstract][Full Text] [Related]
10. CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma. Nishida H; Hayashi M; Morimoto C; Sakamoto M; Yamada T Blood Cancer J; 2018 Oct; 8(11):99. PubMed ID: 30348967 [TBL] [Abstract][Full Text] [Related]
11. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Hideshima T; Cottini F; Ohguchi H; Jakubikova J; Gorgun G; Mimura N; Tai YT; Munshi NC; Richardson PG; Anderson KC Blood Cancer J; 2015 May; 5(5):e312. PubMed ID: 25978432 [TBL] [Abstract][Full Text] [Related]
12. Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase. Gan Y; Shen YH; Wang J; Wang X; Utama B; Wang J; Wang XL J Biol Chem; 2005 Apr; 280(16):16467-75. PubMed ID: 15722551 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Gui CY; Ngo L; Xu WS; Richon VM; Marks PA Proc Natl Acad Sci U S A; 2004 Feb; 101(5):1241-6. PubMed ID: 14734806 [TBL] [Abstract][Full Text] [Related]
14. c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Nebbioso A; Carafa V; Conte M; Tambaro FP; Abbondanza C; Martens J; Nees M; Benedetti R; Pallavicini I; Minucci S; Garcia-Manero G; Iovino F; Lania G; Ingenito C; Belsito Petrizzi V; Stunnenberg HG; Altucci L Clin Cancer Res; 2017 May; 23(10):2542-2555. PubMed ID: 27358484 [No Abstract] [Full Text] [Related]
15. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Scuto A; Kirschbaum M; Buettner R; Kujawski M; Cermak JM; Atadja P; Jove R Cell Death Dis; 2013 May; 4(5):e635. PubMed ID: 23681230 [TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272 [TBL] [Abstract][Full Text] [Related]
17. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197 [TBL] [Abstract][Full Text] [Related]
18. Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation. Tsai PF; Lin SJ; Weng PL; Tsai SC; Lin JH; Chou YC; Tsai CH J Virol; 2011 Mar; 85(5):2373-85. PubMed ID: 21159880 [TBL] [Abstract][Full Text] [Related]
19. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Labisso WL; Wirth M; Stojanovic N; Stauber RH; Schnieke A; Schmid RM; Krämer OH; Saur D; Schneider G Cell Cycle; 2012 Apr; 11(8):1593-602. PubMed ID: 22456335 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone deacetylases by Trichostatin A leads to a HoxB4-independent increase of hematopoietic progenitor/stem cell frequencies as a result of selective survival. Obier N; Uhlemann CF; Müller AM Cytotherapy; 2010 Nov; 12(7):899-908. PubMed ID: 20210674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]